DNA vaccines for prostate cancer

Current Cancer Therapy Reviews

Volumn 8, Issue 4, 2012, Pages 245-253

  McNeel, Douglas G ^a   Becker, Jordan T ^a   Johnson, Laura E ^a   Olson, Brian M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Clinical trials; Dna vaccines; Prostate cancer; Tumor antigens

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIGEN; CANCER VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HLA A2 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; SYNOVIAL SARCOMA X BREAKPOINT 2 ANTIGEN; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFICACY; ELECTROPORATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 84874838131     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339412804143113     Document Type: Review

References (74)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
3. Higano CS, Corman JM, Smith DC, Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 975-984.
4. Emens LA. GM-CSF-secreting vaccines for solid tumors. Curr Opin Investig Drugs 2009; 10: 1315-1324.
5. Wolff JA, Malone RW, Williams P, Chong et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
6. Danko I, Wolff JA. Direct gene transfer into muscle. Vaccine 1994; 12: 1499-1502.
7. Chen Y, Webster RG, Woodland DL. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J Immunol 1998; 160: 2425-2432.
8. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997; 159: 11-14.
9. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8: 108-120.
10. Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 2007; 25 Suppl 2: B24-B34.
11. Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis 2003; 35: 653-659.
12. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501-505.
13. Choubey D, Duan X, Dickerson E, Ponomareva L, Panchanathan R, Shen H, et al. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res 2010; 30: 371-380.
14. Suzuki K, Mori A, Ishii KJ, et al. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A 1999; 96: 2285-2290.
15. Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7: 40-48.
16. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788-792.
17. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006; 25: 135-154.
18. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284-1290.
19. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother 2007; 56: 885-895.
20. Jiao S, Williams P, Berg RK, et al. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 1992; 3: 21-33.
21. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005; 62: 217-223.
22. Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998; 17: 3125-3135.
23. Marshall DJ, San Mateo LR, Rudnick KA, et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother 2005; 54: 1082-1094.
24. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 2001; 7: 882s-889s.
25. Saffran DC, Reiter RE, Jakobovits A, Witte ON. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev 1999; 18: 437-449.
26. Ben Jemaa A, Bouraoui Y, Sallami S, Banasr A, Ben Rais N, Ouertani L, et al. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res 2010; 29: 171.
27. Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004; 22: 1700-1708.
28. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116: 415-421.
29. Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther 2006; 13: 436-444.
30. Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. Eur J Immunol 2011; 41: 2447-2456.
31. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010; 16: 3533-3538.
32. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998; 95: 1735-1740.
33. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008; 68: 861-869.
34. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009; 17: 1101-1108.
35. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001; 61: 5857-5860.
36. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007; 67: 1344-1351.
37. Zhang X, Yu C, Zhao J, et al. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. The journal of gene medicine 2007; 9: 715-726.
38. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998; 10: 609-617.
39. Wells AD, Malkovsky M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today 2000; 21: 129-132.
40. Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother 2009; 58: 1337-1349.
41. Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother 2008; 57: 799-811.
42. Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: many pieces, many puzzles. Biochemical and biophysical research communications 2004; 325: 1115-1121.
43. Hassan MI, Aijaz A, Ahmad F. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev Anticancer Ther 2010; 10: 1055-1068.
44. Hakalahti L, Vihko P, Henttu P, Autio-Harmainen H, Soini Y, Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer 1993; 55: 590-597.
45. Zylka MJ, Sowa NA, Taylor-Blake B, et al. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008; 60: 111-122.
46. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. International journal of clinical and experimental pathology 2011; 4: 295-306.
47. Roiko K, Janne OA, Vihko P. Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatases. Gene 1990; 89: 223-229.
48. Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother 2011; 34: 569-580.
49. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006; 13: 320-327.
50. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91: 688-694.
51. Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005; 28: 389-395.
52. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial. Eur Urol 2000; 38: 208-217.
53. Mincheff M, Altankova I, Zoubak S, et al. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Critical reviews in oncology/hematology 2001; 39: 125-132.
54. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI. DNA vaccines: an active immunization strategy for prostate cancer. Seminars in oncology 2003; 30: 659-666.
55. Slovin S, Gregor P, Wolchok J, et al. A xenogeneic PSMA DNA vaccine for patients with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)-A phase I trial of proof of principle. J Clin Oncology 2007; 25: 3073S.
56. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-1278.
57. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27: 4047-4054.
58. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33: 639-647.
59. Qin H, Zhou C, Wang D, et al. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunology letters 2005; 99: 85-93.
60. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
61. Gray A, de la Garcia-Hernandez M, van West M, Kanodia S, Hubby B, Kast WM. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2009; 27 Suppl 6: G52-G59.
62. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46: 681-686.
63. Healy CG, Simons JW, Carducci MA, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998; 32: 109-119.
64. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-1269.
65. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14: 3536-3544.
66. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Current pharmaceutical design 2002; 8: 1765-1780.
67. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-1271.
68. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 1990; 171: 249-263.
69. Harris TJ, Hipkiss EL, Borzillary S, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008; 68: 1319-1329.
70. Morse MD, McNeel DG. Prostate Cancer Patients Treated with Androgen Deprivation Therapy Develop Persistent Changes in Adaptive Immune Responses. Human immunology 2010; 71: 496-504.
71. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
72. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164: 2160-2169.
73. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer journal (Sudbury, Mass 2010; 16: 311-317.
74. Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PloS one 2009; 4: e7226.